Sana Biotechnology

Sana Biotechnology

Sana Biotechnology is a publicly traded biotechnology company headquartered in Seattle, Washington, with additional facilities in South San Francisco and Cambridge, Massachusetts. The firm focuses on engineered cell therapies, seeking to repair and control genes in cells or replace missing or damaged cells to address the underlying causes of disease. Its strategy spans multiple therapeutic areas, including diabetes, B-cell cancers, and B-cell related autoimmune disorders. The firm integrates expertise from cellular biology, machine learning, and therapeutic development to design novel medicines. It maintains active research and development programs, with a pipeline of drug candidates targeting these disease areas. The geographic footprint covers three major US biotech hubs: Seattle, South San Francisco, and Cambridge. Sana employs a team with backgrounds in cellular biology, machine learning, and drug development. The firm's operations are publicly reported through its SEC filings and investor communications. It has not publicly disclosed team size, AUM, or a detailed organizational structure beyond its research and development focus. Sana is structured as a publicly traded biotechnology company, distinct from a family office or traditional asset manager. Its operations follow corporate governance and public reporting requirements. The firm's unusual mandate — developing engineered cell therapies as medicines — sets it apart from the typical investment or family office model, focusing instead on direct therapeutic innovation.